Drug concentration in lung tissue in multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1750-1752

  Akkerman, Onno W ^a   Van Altena, Richard ^a   Klinkenberg, Theo ^a   Brouwers, Adrienne H ^a   Bongaerts, Alphons H H ^a   Van Der Werf, Tjip S ^a   Alffenaar, Jan Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; ERTAPENEM; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MACROSALB TC 99M; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DRUG SENSITIVITY; DRUG TISSUE LEVEL; FEMALE; GENE; HUMAN; HUMAN TISSUE; KATG GENE; LETTER; LUNG FUNCTION TEST; LUNG INFILTRATE; LUNG SURGERY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RPOB GENE; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY;

ADOLESCENT; ANTITUBERCULAR AGENTS; DRUG MONITORING; FEMALE; HUMANS; LUNG; NETHERLANDS; PNEUMONECTOMY; RADIOGRAPHY, THORACIC; SOMALIA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84890035959     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00047413     Document Type: Letter

References (11)

1. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
2. Bolhuis MS, Altena RV, Soolingen DV, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013 [in press DOI: 10.1183/09031936.00001913].
3. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 2010; 5: 96-114.
4. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
5. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
6. Kjellsson MC, Via LE, Goh A, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 2012; 56: 446-457.
7. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
8. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drugresistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 623-625.
9. Kempker RR, Vashakidze S, Solomonia N, et al. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 157-166.
10. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 6-16.
11. M.T. Mulder-de Jong. Over de tuberkelbacteriën in gereseceerde longdelen [About the tubercle bacilli in resected lung sections]. PhD thesis. University of Groningen, Groningen, the Netherlands, 1960.